302 related articles for article (PubMed ID: 20564622)
1. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
2. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.
Ma Y; Yu WD; Hershberger PA; Flynn G; Kong RX; Trump DL; Johnson CS
Mol Cancer Ther; 2008 Sep; 7(9):3047-55. PubMed ID: 18790784
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D
Bunch BL; Ma Y; Attwood K; Amable L; Luo W; Morrison C; Guru KA; Woloszynska-Read A; Hershberger PA; Trump DL; Johnson CS
Cancer Med; 2019 May; 8(5):2449-2461. PubMed ID: 30972950
[TBL] [Abstract][Full Text] [Related]
4. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system.
Yu WD; Ma Y; Flynn G; Muindi JR; Kong RX; Trump DL; Johnson CS
Cell Cycle; 2010 Aug; 9(15):3022-9. PubMed ID: 20699664
[TBL] [Abstract][Full Text] [Related]
5. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J
Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
[TBL] [Abstract][Full Text] [Related]
7. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
Isono M; Okubo K; Asano T; Sato A
Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
[TBL] [Abstract][Full Text] [Related]
9. Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Palmeira C; Colaço A; Moreira da Silva V; Oliveira P; Lara Santos L
Urol Oncol; 2014 Jan; 32(1):41.e11-22. PubMed ID: 24035472
[TBL] [Abstract][Full Text] [Related]
10. Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
Zhu HQ; Ma JB; Song X; Gao HJ; Ma CQ; Chang H; Li HG; Liu FF; Lu J; Zhou X
Oncol Rep; 2016 Dec; 36(6):3488-3496. PubMed ID: 27779693
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D increases the efficacy of cisplatin on bladder cancer cell lines.
Özgen Ö; Özen Eroğlu G; Küçükhüseyin Ö; Akdeniz N; Hepokur C; Kuruca S; Yaylım İ
Mol Biol Rep; 2023 Jan; 50(1):697-706. PubMed ID: 36370297
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor effects and cell motility inhibition of the DN604-gemcitabine combined treatment in human bladder cancer models.
Wang X; Chen F; Gou S
Bioorg Med Chem; 2021 Jan; 29():115858. PubMed ID: 33218897
[TBL] [Abstract][Full Text] [Related]
13. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.
Zhang J; Miao L; Guo S; Zhang Y; Zhang L; Satterlee A; Kim WY; Huang L
J Control Release; 2014 May; 182():90-6. PubMed ID: 24637468
[TBL] [Abstract][Full Text] [Related]
16. Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer.
Sun M; Zhao W; Xie Q; Zhan Y; Wu B
Surg Oncol; 2015 Mar; 24(1):28-34. PubMed ID: 25434982
[TBL] [Abstract][Full Text] [Related]
17. Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer.
Xiong Q; Liu A; Ren Q; Xue Y; Yu X; Ying Y; Gao H; Tan H; Zhang Z; Li W; Zeng S; Xu C
Cell Death Dis; 2020 May; 11(5):366. PubMed ID: 32409654
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression.
Hershberger PA; McGuire TF; Yu WD; Zuhowski EG; Schellens JH; Egorin MJ; Trump DL; Johnson CS
Mol Cancer Ther; 2002 Aug; 1(10):821-9. PubMed ID: 12492115
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.
Krause S; Förster Y; Kraemer K; Fuessel S; Kotzsch M; Schmidt U; Wirth MP; Meye A; Schwenzer B
J Urol; 2005 Jul; 174(1):328-31. PubMed ID: 15947684
[TBL] [Abstract][Full Text] [Related]
20. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
